Remove Heart Failure Remove Heart Valves Remove Innovation
article thumbnail

Ismail El-Hamamsy, MD, PhD, Named President of the Heart Valve Society

DAIC

Griepp , MD Professor in Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai , was named as the new President of the Heart Valve Society ( HVS ) at the 2024 HVS Annual Meeting on Wednesday, February 21, in Boston.

article thumbnail

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

DAIC

mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.

article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 TR occurs when the valve doesn't close properly, causing a leak and allowing blood to flow backward in the heart. Abbott has announced U.S million people in the U.S.

Tricuspid 105
article thumbnail

Columbia Cardiology Launches New Mitral & Tricuspid Center

DAIC

Tricuspid and mitral valves are debilitating conditions that can lead to arrhythmias, hypertension, and heart failure. Until recently, therapeutic options for people with tricuspid and mitral valve disorders have been limited to symptom relief or high-risk surgery.

Tricuspid 111
article thumbnail

New Treatment Options Available for Patients with Tricuspid Valve Disease

DAIC

Catheter-based procedures offer an alternative for patients who are not candidates for open-heart surgery. Raj Makkar, MD: Tricuspid regurgitation is a condition where the tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium.

article thumbnail

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker

DAIC

Tricuspid regurgitation (TR) is a common and serious disease for which open heart surgery and symptomatic pharmacologic treatment are the current standard treatment options. Topaz is an innovative, minimally invasive device designed specifically to help patients suffering from severe TR, without the need for open heart surgery.

article thumbnail

The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device

DAIC

suffer from heart failure , and there are approximately 400,000 heart-failure-related deaths in this country each year. Patients with heart failure often experience reduced mobility, quality of life and ability to work; the disease also represents a significant public health care burden.